OneCyte and Kemp Proteins Announce Strategic Partnership for Next-Gen Biologics

The collaboration aims to accelerate high-performance cell line development for complex and difficult-to-express biologics.

Apr. 3, 2026 at 12:39pm

Got story updates? Submit your updates here. ›

A highly textured, abstract painting in soft blues, greens, and grays, featuring sweeping geometric arcs, concentric cellular structures, and precise molecular spirals, conceptually representing the innovative collaboration between OneCyte and Kemp Proteins to advance cell line development for next-generation biologics.A strategic partnership leveraging cutting-edge single-cell and protein engineering technologies aims to accelerate the development of complex biopharmaceuticals.Frederick Today

OneCyte, a leader in single-cell analysis and cell line development technologies, and Kemp Proteins, an expert in protein engineering and expression solutions, have announced a strategic partnership to deliver industry-leading cell line development services for biopharmaceutical companies worldwide. This collaboration combines OneCyte's high-throughput single-cell platform with Kemp's advanced molecular engineering capabilities, including its proprietary machine learning-driven platform PROTiQ, to enable faster development timelines, higher titers, and successful expression of complex and difficult-to-express biologics.

Why it matters

Biopharma companies continue to face significant challenges in cell line development, including long development cycles, suboptimal yields, and high failure rates, particularly for novel and complex molecules. This partnership aims to address these pain points by integrating predictive in silico design with rapid and high-throughput experimental validation, providing a powerful and differentiated solution for global biopharma customers.

The details

The combined offering provides access to a royalty-free CHO-K1 GS knockout cell line and transposase-based expression system, enabling flexible and efficient development without restrictive licensing constraints. The integrated approach is designed to adapt quickly to the evolving needs of new therapeutic modalities, delivering both speed and performance without compromise.

  • The partnership was announced on April 3, 2026.

The players

OneCyte

A biotechnology company focused on transforming cell line development through high-throughput single-cell technologies. Its proprietary platform enables rapid, high-sensitivity analysis and selection of elite producer cells, accelerating timelines while improving productivity and consistency.

Kemp Proteins

A leading provider of protein engineering and expression services, specializing in the development of difficult-to-express and complex biologics. Leveraging advanced computational tools, including its proprietary PROTiQ platform, and decades of expertise, Kemp enables efficient design, optimization, and production of high-quality therapeutic proteins for global biopharma partners.

Got photos? Submit your photos here. ›

What they’re saying

“We are thrilled to be working with Kemp to provide industry-leading cell line development services to the biopharma industry. By combining our single-cell technology with Kemp's deep expertise in protein expression, we are confident that we can address the hardest challenges associated with new modalities, delivering faster timelines and industry-leading titers.”

— Dr. Konstantinos Tsioris, Co-founder and President of OneCyte

“As Kemp has been at the forefront of protein expression for many years, this partnership positions us to extend and strengthen that leadership. OneCyte's class-leading single-cell technology, stacked on top of our molecular design and expression capabilities, will provide a powerful and differentiated solution for our global biopharma customers.”

— Michael Keefe, CEO of Kemp Proteins

What’s next

The partnership is expected to immediately begin delivering industry-leading cell line development services to biopharma companies worldwide.

The takeaway

This strategic partnership between OneCyte and Kemp Proteins combines cutting-edge single-cell analysis and protein engineering technologies to address the key challenges in cell line development for complex and difficult-to-express biologics, accelerating timelines and improving productivity for the biopharma industry.